Zoledronic acid (ZOL) significantly increases progression-free survival (FPS) versus clodronate and may improve response rates in newly diagnosed multiple myeloma (MM): MRC myeloma IX trail results

Authors
Publication date
Publisher
Fondazione Ferrata Storti

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Newcastle University E-Prints

    redirect
    oaioai:eprints.ncl.ac.uk:161798
    Last time updated on 30/05/2021